Analysis of the Current Status and Characteristics of Health Economics Reporting in Clinical Practice Guidelines for 2021–2023

Current CPGs and expert consensus statements exhibit low rates of HE evidence reporting, indicating that most international guideline developers have overlooked their applications. HE evidence-through cost-effectiveness and cost-utility analyses-can optimize medical resource allocation, support clinicians in patient-centered economic decision-making, and enhance health outcomes. Future guideline development should prioritize HE evidence integration to advance the scientific rigor and clinical applicability of the recommendations.